Image Description (1 Formula)
Felodipine Tablet, Film Coated
Product Images NDC 61442-433
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Felodipine (NDC 61442-433). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Carlsbad Technology, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image Description (10mg 500ct Label)
This is a description of Felodipine, an extended-release tablet with 10mg content per tablet. It has usual adult dosage, which is given along with prescribing information. The tablets should be swallowed whole and not crushed or chewed. The tablet must be preserved in a light-resistant container as defined in the USP, stored in 20° to 25°C (88°to T7°F) room temperature. It is manufactured by Carlsbad Technology Inc. and distributed by Carisbad Technology.*
Image Description (2.5mg 500ct Label)
NDC 61442-431-05 is a prescription drug that contains 25g felodipine in extended-release tablets, it is recommended to swallow the tablets whole and dispense in a light-resistant container. The usual adult dosage is provided in the prescribing information. It should be stored at room temperature and kept out of reach of children with the container tightly closed. Manufacturer of the drug is Carlsbad Technology, Inc. Some errors exist in the text.*
Image Description (5mg 500ct Label)
This is a description for Felodipine Extended-Release tablets, USP. The usual adult dosage should be obtained from the accompanying prescribing information. These tablets should not be chewed and should be kept in a light-resistant container. They should also be stored between 20°C and 25°C. The medication should be kept away from children and the container should be tightly closed. The tablets have been manufactured by 5622 Farnsworth and distributed by Carisbad Technology, Inc. There is additional contact information for Yiing Shin Pharmaceutical Ind. Co., L. in Taichung, Taiwan.*
Table 1 (Table 1)
The text provides mean reductions in blood pressure (measured in mmHg) in two different studies evaluating the effects of different doses of a medication over a period of either four or eight weeks. The first study tested doses of 5mg, 10mg, and 25mg, while the second study tested doses of 0mg and 20mg. In addition to the mean trough response (at the end of the dosing interval), the text also provides the mean peak response to the medication. However, the number of patients available for peak and trough measurements varies and the placebo response was subtracted.*
Table 2 (Table 2)
The text describes the percentage of patients experiencing adverse events in controlled trials of extended-release tablets of Felodipine, without considering the causality, and also mentions the incidence of discontinuations. The adverse events and their corresponding incidence rates are differentiated and tabulated according to body systems. The text also suggests that patients in titration studies may have been exposed to more than one dose of felodipine extended-release tablets.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
